Cargando…
Cancer drugs: high price, uncertain value
A study published in The BMJ this week shows how most new cancer drugs are failing to deliver any clinically meaningful benefit. It’s time for Europe to raise the evidence bar before market approval, finds Deborah Cohen
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group Ltd.
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5695518/ https://www.ncbi.nlm.nih.gov/pubmed/28978508 http://dx.doi.org/10.1136/bmj.j4543 |